AGEN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Sharp Revenue And Earnings ImprovementThe latest TTM results show a substantial improvement in revenue and reported profitability after several years of losses. If Agenus can convert this improvement into repeatable collaboration, licensing, or product-related economics, it could strengthen internal funding capacity and support development of its pipeline.
Strategic Focus On A Lead Clinical ProgramConcentrating resources on a defined Phase 3 program can improve execution discipline and reduce the risk of spreading capital across too many initiatives. The targeted colon cancer setting and reported Phase 2 response data provide a clearer development path for potentially creating future partnership or product value.
Extended Operating RunwayThe financing provides Agenus with a meaningful period to advance its lead program and reach important clinical milestones without requiring immediate additional funding under the stated base case. More time to execute can improve negotiating flexibility and allow clinical catalysts to develop before another capital raise.
Bears Say
Negative Shareholder EquityNegative equity reflects accumulated losses and leaves the company with a thin capital base relative to its obligations. This reduces financial flexibility, can complicate future financing, and increases the likelihood that additional capital may need to come from equity-linked instruments rather than internally generated resources.
Persistent Cash ConsumptionAgenus continues to consume substantial cash despite the improvement from 2025, indicating that reported earnings have not yet translated into durable cash generation. Ongoing clinical development and operations therefore remain dependent on external financing, increasing funding risk over the next several quarters.
Volatile And Non-recurring Revenue ModelThe company’s clinical-stage model makes revenue dependent on contract timing, milestone achievement, licensing activity, and external service demand rather than established product sales. This can produce uneven results and makes current profitability harder to extrapolate until sustained commercial or royalty revenue develops.
Agenus News
AGEN FAQ
What was Agenus’s price range in the past 12 months?
Currently, no data Available
What is Agenus’s market cap?
Agenus’s market cap is CHF373.58M.
When is Agenus’s upcoming earnings report date?
Agenus’s upcoming earnings report date is Nov 10, 2026 which is in 40 days.
How were Agenus’s earnings last quarter?
Agenus released its earnings results on Aug 06, 2026. The company reported -CHF0.008 earnings per share for the quarter, missing the consensus estimate of CHF0.038 by -CHF0.046.
Is Agenus overvalued?
According to Wall Street analysts Agenus’s price is currently Undervalued.
Does Agenus pay dividends?
Agenus does not currently pay dividends.
What is Agenus’s EPS estimate?
Agenus’s EPS estimate is -0.22.
How many shares outstanding does Agenus have?
Currently, no data Available
What happened to Agenus’s price movement after its last earnings report?
Agenus reported an EPS of -CHF0.008 in its last earnings report, missing expectations of CHF0.038. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Agenus?
Currently, no hedge funds are holding shares in CH:AGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agenus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF20.49 (― Upside)
CHF20.49 (― Upside)
Blogger Sentiment
Bullish
CH:AGEN Sentiment 67%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Agenus
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
AGEN Stock 12 Month Forecast
Average Price Target
―Inovio Pharmaceuticals
―
Oncolytics Biotech
―
―
TuHURA Biosciences
―
Spero Therapeutics
―
Instil Bio
―